Real-World Experience With Initiating Buprenorphine in Opioid Tolerant Patients with Cancer Pain

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Full-opioid agonists are standard for cancer pain but carry significant risks like constipation and respiratory depression.
• Buprenorphine, a partial opioid agonist, presents a potentially safer alternative, yet concerns about withdrawal and efficacy persist.
• This study investigates the real-world application of buprenorphine in opioid-tolerant cancer patients.

Purpose of the Study:

• To assess the success rate of initiating buprenorphine products in opioid-tolerant patients with cancer-related pain.
• To evaluate clinical outcomes, including pain control, withdrawal symptoms, and discontinuation rates.
• To determine the viability of buprenorphine as an alternative to full-opioid agonists in this population.

Main Methods:

• Retrospective, single-center study of adult patients with active or historical malignancy initiating transdermal or buccal buprenorphine.
• Inclusion criteria: opioid tolerance and initiation between January 2023 and June 2024.
• Primary outcome: successful initiation at 30 days, defined by continued use, absence of withdrawal, and stable/improved pain.

Main Results:

• 48 patients met inclusion criteria; 71% achieved successful buprenorphine initiation at 30 days.
• Mean pain scores decreased from 6.3 to 4.9. Withdrawal symptoms occurred in 8% of patients.
• 77% remained on buprenorphine at 30 days, with 65% staying on their initial dose.

Conclusions:

• Buprenorphine demonstrates safety and efficacy for cancer-related pain management in opioid-tolerant patients.
• Minimal withdrawal symptoms and stable/improved pain control support its use.
• Findings suggest broader adoption of buprenorphine, with a call for further prospective research.